 Keep reading to see why (MDCX) is topping our watchlist this morning—Tuesday, March 3rd, 2026.
 Dear Reader, The global basal cell carcinoma treatment market is projected to reach USD $5.93B by 2030, here's what caught my attention—the intralesional injections segment is anticipated to grow at the fastest rate. At the center of this expanding space sits a company quietly pioneering non-invasive approaches to skin cancer treatment, while simultaneously advancing a next-generation hormone therapy with potential to reshape how we treat advanced prostate cancer. Medicus Pharma Ltd. (NASDAQ: MDCX) is topping our watchlist this morning—Tuesday—March 3rd, 2026. Here's what stands out: according to Yahoo Finance, (MDCX) has approximately 14.83M shares in its public float. Combined with a market cap around $38.75M, the potential exists for big moves if demand shifts. Keep in mind—when small floats meet potential catalysts, volatility could pop up in a flash. Medicus Pharma is a precision-guided biotech company advancing two clinical-stage assets. SkinJect™ is a proprietary dissolvable microneedle array platform designed to non-invasively treat basal cell carcinoma. Teverelix® is a next-generation long-acting antagonist targeting advanced prostate cancer patients with high cardiovascular risk. Key Milestones Driving Momentum- SkinJect™ Phase 2 Enrollment Complete: According to the December 15 press release, (MDCX) completed enrollment of 90 patients across nine U.S. clinical sites. Topline results expected Q1 2026.
- FDA Clears Teverelix® Phase 2b: As announced in the February 10 press release, (MDCX) received "study may proceed" clearance for its prostate cancer trial targeting patients with elevated CV risk.
- AI Partnership: The December 22 announcement revealed collaboration with Reliant AI—featuring ex-DeepMind/Google Brain talent—for clinical data analytics.
- Women's Health Data at AACE: Per the January 12 press release, Phase 1 Teverelix® data in 48 women showed favorable safety and stable bone turnover.
Market Alignment Worth NotingPer Grand View Research, the BCC treatment market could expand to $5.93B by 2030. The prostate cancer hormone therapy market? Fortune Business Insights projects growth to $83.1B by 2034. Combined, (MDCX) targets approximately $8B in addressable markets. 4 Reasons (MDCX) Tops Our Watchlist Today1. Imminent Phase 2 Readout: SkinJect™ topline data expected Q1 2026—interim analysis already showed >60% clinical clearance. 2. FDA Clearance Just Received: Teverelix® Phase 2b now cleared to proceed, targeting a $6B+ combined market for prostate cancer patients with CV risk. 3. Analyst Coverage Signals Upside:D. Boral Capital maintains a bullish rating with a $27 price target—which suggests a potential upside of 2,300% from current levels near $1.08. 4. AI-Enabled Clinical Strategy: Partnership with Reliant AI brings ex-DeepMind expertise to optimize patient stratification and enrollment forecasting. Take a look at the technical data from Yahoo Finance—(MDCX) currently trades well below its 200-day moving average of $2.41, with its 52-week range spanning $0.92 to $8.94. From these chart levels, could a reversal be setting up? Pull Up MDCX This Tuesday Morning…From its imminent SkinJect™ Phase 2 readout to the recent FDA clearance for Teverelix®, (MDCX) is entering a catalyst-rich window. Analyst targets suggest substantial upside potential, and the dual-asset pipeline targets very large markets in oncology supportive care and hormone therapy. We have all eyes on (MDCX) this morning—Tuesday, March 3rd, 2026. Sincerely, Sources:
Tuesday's Featured Content Defense Stocks Are Soaring—AeroVironment's Earnings Could Close the GapWritten by Chris Markoch. Publication Date: 3/2/2026. 
Key Points- AeroVironment stock has dropped roughly 15% in 30 days and trails the SPDR S&P Aerospace & Defense ETF by a wide margin, even as defense spending tailwinds accelerate.
- Revenue through the first half of fiscal 2026 surged 145% year over year, and the company posted a record $3.5 billion in quarterly contract awards.
- Adjusted gross margins fell to 27% from 41% a year ago, and the margin recovery timeline is the key variable heading into March 3 earnings.
- Special Report: Disrupting the Future of Pest Control (From Med-X)
Nearly two months into 2026, many aerospace stocks are outperforming the S&P 500, as reflected by the SPDR S&P Aerospace & Defense ETF (NYSEARCA: XAR). The fund is up about 16.2%, while the S&P 500 is up just over 1%. That makes AeroVironment Inc. (NASDAQ: AVAV) a relative laggard in the sector. AVAV is up about 5.5% year-to-date, but that masks a steep selloff over the past month. Fraud is being exposed everywhere right now. Billions gone.
But they're missing the big one...
A legal scam that affects 95% of ALL Americans.
Oxford Club's own Marc Lichtenfeld hit the streets of South Florida to expose it in broad daylight.
Watch along as he captures real people's reactions LIVE on camera. Click Here to Watch What Happens More strikingly, the XAR is up more than 22% over the last three months, while AVAV stock is down more than 8% over the same period. Investors will be closely watching AeroVironment as it prepares to report earnings on March 3. Growing in a High-Growth SectorMany proposals in the annual State of the Union amount to political rhetoric — they can sound ambitious but often fail to pass unchanged or get substantially watered down. Still, the themes from those proposals can signal where government spending may be directed. Here's how that relates to AeroVironment. The company focuses on three specific categories: - Unmanned Aerial Systems (UAS)
- Tactical missiles and precision loitering munitions
- Electric vehicle charging and scalable energy systems
All three are part of the "next-generation" defense technologies that proposals in Washington envision supporting — including plans the Trump administration has discussed to spend up to $1 trillion to rebuild U.S. defense capabilities. That potential support has already shown up in AeroVironment's numbers. Through the first two quarters of its fiscal 2026 year, revenue is up 145% year-over-year. In its Q2 fiscal year (FY2026) earnings report, AeroVironment guided full-year revenue to between $1.95 billion and $2.0 billion — more than double its first-half revenue. The company attributed the gains to strong demand for drones and precision-strike products and recorded a company high of $3.5 billion in contract awards during the quarter. Another factor investors consider is geopolitical risk. The prospect of U.S. military action in Iran, for example, could increase demand for AeroVironment's unmanned systems and precision weapons. Can Earnings and Margins Catch Up?As with many growth companies, AVAV's valuation question centers on timing: when will the strong top-line growth translate into higher earnings? Adjusted gross margins declined to 27%, down sharply from 41% in the same quarter a year earlier. Management cited three main drivers: the mid-quarter rollout of a new Oracle financial system that created one-time inefficiencies and costs; a shift in revenue mix toward lower-margin services after the BlueHalo acquisition; and a prolonged U.S. government shutdown that delayed product shipments — including some international sales — which weighed on higher-margin product revenue. Management expects margins to recover into the high-30% range by Q4, supported by a ramp in product revenues, completion of the software transition, and revenue from pent-up government orders beginning to flow through. If that margin recovery materializes, it would support analysts' forecasts for roughly 31% earnings growth over the next 12 months and help justify the company's current valuation of about 15x sales. Bullish Sentiment Could Signal an Earnings BeatAeroVironment is covered by 23 analysts and has a consensus rating of Moderate Buy, with 20 analysts rating the stock a Buy. The consensus price target of $367 implies about a 42% upside from the AVAV share price at the time of writing. According to MarketBeat data, institutional buying has outpaced selling by nearly a 2:1 margin over the past 12 months. The optimism is tied in part to the earnings outlook. The consensus forecast calls for adjusted EPS of $0.73. The whisper number — an unofficial Street estimate — sits at $0.66, suggesting some analysts view the consensus as roughly 10% high. Even using the more conservative whisper number, EPS would represent a year-over-year gain of over 100% from last year's level. That kind of YoY earnings growth has not yet appeared in AeroVironment's reported results for the first two quarters of the fiscal year.
This message is a paid advertisement for Medicus Pharma Ltd. (NASDAQ: MDCX) from Create New Advertiser and Organized Noise. MarketBeat Media, LLC receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $13,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Create New Advertiser or Organized Noise. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding Medicus Pharma Ltd. (NASDAQ: MDCX) on Organized Noise' website for additional information about the relationship between Organized Noise and Medicus Pharma Ltd. (NASDAQ: MDCX). | 
Tidak ada komentar:
Posting Komentar